Over last three decades we have developed antibody therapies against a host of diseases including autoimmune, infectious diseases and cancer.
Traditional technologies are unable to screen the entire B cell repertoire. As a result antibody therapies have only been developed against simple
targets with limited success for more difficult targets such as GPCRs and ion channels. To access these new antibodies against more difficult
targets, the high-hanging fruit, will require technology that can functionally screen the entire B cell repertoire. Here we demonstrate how Plasma
B Discovery on the Beacon® optofluidic platform can be used to access and functionally screen broad B cell diversity to discover thousands of hits
and recover >650 unique, functional antigen-specific antibody sequences in a single workflow that takes less than 1 week.